Embodiments described herein relate to devices and methods that can be used to treat a wound with negative pressure. Particular embodiments can also be useful to aid in wound closure, for example in abdominal wounds.
In the prior art, application of negative pressure may sometimes exert an outward force upon the wound margins due to the atmospheric pressure compressing the wound filler downward and outward against the margins of the wound. This downward compression of the wound filler slows the healing process and slows or prevents wound closure. Accordingly, there is a need to provide for an improved apparatus, method, and system for the treatment and closure of wounds.
Generally, the embodiments described herein can be used to assist in the treatment of wounds with negative pressure. The embodiments can be particularly useful in treating large wounds, such as abdominal wounds, where closure and approximation of the wound edges is challenging. By limiting the amount of vertical pressure applied to the wound filler, by enhancing the horizontal collapse of the wound filler, and by enhancing attachment of the wound filler to the wound margins, together with additional details described herein, improved wound closure can be obtained.
In some embodiments, a wound filler for use in treating a wound with negative pressure comprises:
In certain embodiments, the vertically extending members can be struts, slabs, columns or tiles. In some embodiments, the vertically extending members of any of the aforementioned wound filler embodiments are elongate members configured to extend lengthwise across a wound bed and are aligned parallel to one another. In particular embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can surround the vertically extending members. In some embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can extend between the vertically extending members. In particular embodiments, the porous wound filling material of any of the aforementioned wound filler embodiments can comprise a plurality of slits or areas in which denser or more rigid struts or slabs are inserted.
In particular embodiments, the wound fillers of any of the aforementioned embodiments can include flexible material positioned between the vertically extending members to allow compression of the vertically extending members towards each other in a horizontal plane when the wound filler is positioned within a wound bed and is placed under negative pressure. In some embodiments, the vertically extending members of any of the aforementioned wound filler embodiments can be adhered to the porous wound filling material.
In some embodiments, one or more draw strings or cords can extend through the wound filler such that pulling of the draw strings causes contraction of the wound filler in a horizontal plane.
In certain embodiments, a negative pressure wound therapy system comprises a wound filler such as those described herein and a wound cover configured to be placed over the wound filler. In certain embodiments, the negative pressure wound therapy system described above further includes a connection for connecting the wound cover to a source of negative pressure. In some embodiments, the aforementioned negative pressure wound therapy system further comprises a negative pressure source configured to be connected to the wound cover to provide negative pressure to the wound filler when placed within the wound bed.
In some embodiments, a method of treating a wound comprises:
Other embodiments of wound closure devices, stabilizing structures and associated apparatuses are described below.
Other features and advantages of the present invention will be apparent from the following detailed description of the invention, taken in conjunction with the accompanying drawings of which:
Embodiments of wound fillers and other wound treatment apparatuses and methods that may be utilized with and/or that may provide further details regarding the embodiments described below are found in U.S. Provisional Application No. 61/651,483, filed May 24, 2012, the entirety of which is hereby incorporated by reference and portions of which are included below in the section titled “Other Negative Pressure Therapy Apparatuses, Dressings, Wound Fillers, and Methods.”
Various embodiments that can be used for the treatment of wounds will now be described with references to the following figures and description which follow. It will be of course understood that various omissions, substitutions, and changes in the form and details of the embodiments illustrated can be made without departing from the spirit of the disclosure. Additionally, the various features and processes described herein can be used independently of one another, or can be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Many of the embodiments described herein include similar components, and as such, these similar components can be interchanged in different embodiments.
Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including pump and wound dressing components and apparatuses. Generally, the embodiments including the wound fillers described herein may be used in combination with a negative pressure system comprising a drape or wound cover placed over the filler. A vacuum source, such as a pump, may be connected to the cover, for example, through one or more tubes connected to an aperture or port made in or under the cover. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings. Reference is made to the following applications, which are hereby incorporated by reference in their entireties: U.S. application Ser. No. 12/886,088, titled “SYSTEMS AND METHODS FOR USING NEGATIVE PRESSURE WOUND THERAPY TO MANAGE OPEN ABDOMINAL WOUNDS”, published as US 2011/0213287 on Sep. 1, 2011; and U.S. application Ser. No. 13/092,042, titled “WOUND DRESSING AND METHOD OF USE”, published as US 2011/0282309 on Nov. 17, 2011.
It will be appreciated that throughout this specification reference is made to a wound or wounds. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured, or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, acute wounds, chronic wounds, surgical incisions and other incisions, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. In some embodiments, the components of the negative pressure treatment system described herein can be particularly suited for incisional wounds that exude a small amount of wound exudate.
As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760-X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).
The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even 150 mmHg, can be supplied by the negative pressure apparatus.
As used herein, the term “horizontal.” when referring to a wound, indicates a direction or plane generally parallel to the skin surrounding the wound. The term “vertical,” when referring to a wound, generally refers to a direction extending perpendicular to the horizontal plane. The term “longitudinal,” when referring to a wound, generally refers to a direction in the horizontal plane taken in a direction along which the wound is longest. The term “lateral,” when referring to a wound, generally refers to a direction in the horizontal plane perpendicular to the longitudinal direction. The terms “horizontal,” “vertical,” “longitudinal,” and “lateral” can also be used to describe the wound fillers or other devices described throughout this specification. When describing these wound fillers or devices, these terms should not be construed to require that the structures or devices necessarily be placed into a wound in a certain orientation, though in certain embodiments, it may be preferable to do so.
As used herein, the term “fill material” comprises, in a non-limiting manner: porous wound filler materials and flexible materials. As used herein, compressible materials are included within the scope of flexible materials.
Turning to
In cases where there is a wound, particularly in the abdomen, management of possible complications relating to the exposure of organs and the peritoneal space is desired, whether or not the wound is to remain open or if it will be closed. Therapy, preferably using the application of negative pressure, can be targeted to minimize the risk of infection, while promoting tissue viability and the removal of deleterious substances from the wound site. The application of reduced or negative pressure to a wound site has been found to generally promote faster healing, increased blood flow, decreased bacterial burden, increased rate of granulation tissue formation, to stimulate the proliferation of fibroblasts, stimulate the proliferation of endothelial cells, close chronic open wounds, inhibit burn penetration, and/or enhance flap and graft attachment, among other things. It has also been reported that wounds that have exhibited positive response to treatment by the application of negative pressure include infected open wounds, decubitus ulcers, dehisced incisions, partial thickness burns, and various lesions to which flaps or grafts have been attached. Consequently, the application of negative pressure to a wound site 110 can be beneficial to a patient.
Accordingly, certain embodiments provide for a wound contact layer 105 to be placed over the wound site 110. Preferably, the wound contact layer 105 can be a thin, flexible material which will not adhere to the wound site or the exposed viscera in close proximity. For example, polymers such as polyurethane, polyethylene, polytetrafluoroethylene, or blends thereof may be used. In one embodiment, the wound contact layer is permeable. For example, the wound contact layer 105 can be provided with openings, such as holes, slits, or channels, to allow the removal of fluids from the wound site 110 or the transmittal of negative pressure to the wound site 110.
Certain embodiments of the negative pressure treatment system 101 may also use a porous wound filler 103, which can be disposed over the wound contact layer 105. This pad 103 can be constructed from a porous material, for example foam, that is soft, resiliently flexible, and generally conformable to the wound site 110. Such a foam can include an open-celled and reticulated foam made, for example, of a polymer. Suitable foams include foams composed of, for example, polyurethane, silicone, and polyvinyl alcohol. Preferably, this pad 103 can channel wound exudate and other fluids through itself when negative pressure is applied to the wound. Some pads 103 may include preformed channels or openings for such purposes. In certain embodiments, the pad 103 may have a thickness between about one inch and about two inches. The pad may also have a length of between about 16 and 17 inches, and a width of between about 11 and 12 inches. In other embodiments, the thickness, width, and/or length can have other suitable values. Other embodiments of wound fillers that may be used in place of or in addition to the pad 103 are discussed in further detail below.
Preferably, a drape 107 is used to seal the wound site 110. The drape 107 can be at least partially liquid impermeable, such that at least a partial negative pressure may be maintained at the wound site. Suitable materials for the drape 107 include, without limitation, synthetic polymeric materials that do not significantly absorb aqueous fluids, including polyolefins such as polyethylene and polypropylene, polyurethanes, polysiloxanes, polyamides, polyesters, and other copolymers and mixtures thereof. The materials used in the drape may be hydrophobic or hydrophilic. Examples of suitable materials include Transeal® available from DeRoyal and OpSite® available from Smith & Nephew. In order to aid patient comfort and avoid skin maceration, the drapes in certain embodiments are at least partly breathable, such that water vapor is able to pass through without remaining trapped under the dressing. An adhesive layer may be provided on at least a portion the underside of the drape 107 to secure the drape to the skin of the patient, although certain embodiments may instead use a separate adhesive or adhesive strip. Optionally, a release layer may be disposed over the adhesive layer to protect it prior to use and to facilitate handling the drape 107; in some embodiments, the release layer may be composed of multiple sections.
The negative pressure system 101 can be connected to a source of negative pressure, for example a pump 114. One example of a suitable pump is the Renasys EZ pump available from Smith & Nephew. The drape 107 may be connected to the source of negative pressure 114 via a conduit 112. The conduit 112 may be connected to a port 113 situated over an aperture 109 in the drape 107, or else the conduit 112 may be connected directly through the aperture 109 without the use of a port. In a further alternative, the conduit may pass underneath the drape and extend from a side of the drape. U.S. Pat. No. 7,524,315 discloses other similar aspects of negative pressure systems and is hereby incorporated by reference in its entirety and should be considered a part of this specification.
In many applications, a container or other storage unit 115 may be interposed between the source of negative pressure 114 and the conduit 112 so as to permit wound exudate and other fluids removed from the wound site to be stored without entering the source of negative pressure. Certain types of negative pressure sources—for example, peristaltic pumps—may also permit a container 115 to be placed after the pump 114. Some embodiments may also use a filter to prevent fluids, aerosols, and other microbial contaminants from leaving the container 115 and/or entering the source of negative pressure 114. Further embodiments may also include a shut-off valve or occluding hydrophobic and/or oleophobic filter in the container to prevent overflow; other embodiments may include sensing means, such as capacitive sensors or other fluid level detectors that act to stop or shut off the source of negative pressure should the level of fluid in the container be nearing capacity. At the pump exhaust, it may also be preferable to provide an odor filter, such as an activated charcoal canister.
In some embodiments, the extending members 204 are denser than the fill material 202. In some embodiments, the extending members 204 are between 1 to 2 times, between 2 to 4 times, between 4 to 6 times, between 6 to 8 times, or 8 times or more dense than the fill material. In certain embodiments, the extending members 204 are more rigid than the fill material 202. In some embodiments, the extending members are between 1 to 2 times, between 2 to 4 times, between 4 to 6 times, between 6 to 8 times, or 8 times or more rigid than the porous wound filling material.
In certain preferable embodiments, and as also shown in
The extending members 204 may be parallel or substantially parallel to one another, and may be spaced apart 204 either equally or unequally. In horizontal cross-section as shown in
In some embodiments, as shown in
As shown in
In some embodiments, upon application of negative pressure to the wound filler 200), for example, using the system previously described with respect to
In any of the embodiments herein described, the wound filler can be cut to an appropriate shape and size to fit within the wound. The wound filler can be trimmed to shape in any manner, for example by trimming around the circumference of an oval wound filler or by trimming the horizontal edges of a square or rectangular wound filler.
In some embodiments, after the wound filler is appropriately sized, the extending members can be aligned such that, when placed in a wound cavity, they are perpendicular and extend in a vertical direction from the wound bed. In certain embodiments, application of a vacuum can then cause the fill material to contract substantially only in the horizontal plane, as the extending members reduce movement in the vertical direction (and may also resist horizontal movement). In some embodiments, the compression of the filler can aid in closing the wound cavity in the horizontal plane.
In some embodiments, preferably applicable to the embodiments described in
In any of the embodiments described herein, the extending members can be made from rigid plastics such as polystyrene, polycarbonate, poly(meth)acrylates, semi-rigid materials such as silicone, or from rigid foams or felted flexible foams. In some embodiments, felted flexible foams can be made by subjecting flexible foams, e.g. those used as the porous compressible filler, to heat and pressure to produce a dense, semi-rigid foam that is still porous. Such a configuration can also enhance horizontal movement so as to permit greater wound closure.
In some embodiments (not shown but described as FIG. 2 in Provisional Application No. 61/651,483), a wound filler is provided comprising a minimally-compressible central core surrounded by a compressible outer layer. Such a configuration can reduce vertical movement and permit the wound edge to move inward in a direction toward the central core, thereby aiding in closing the wound. Further, the amount of closure can be controlled by varying the size of the central core. In some embodiments, the central core comprises one or more of a rigid foam, closed cell foam, and silicone elastomers or rigid flexible foam. Further embodiments may also comprise alternating concentric rings of more rigid (or more dense) material and less rigid (or less dense) material.
In certain embodiments (not shown but described as FIG. 3 in Provisional Application No. 61/651,483), an embodiment may be configured in the opposite manner as the embodiment described in the paragraph above, with a minimally-compressible outer layer surrounding a compressible core. The minimally-compressible outer layer can be configured to resist vertical compression, while the compression of the central core can aid in wound closure. As with the embodiment of the previous paragraph, this embodiment can be arranged in a concentric circle or oval configuration, or a linear configuration.
In the embodiment of
In some embodiments, the rigid columns can comprise rigid plastic such as polystyrene, polycarbonate or a semi-rigid material such as a silicone. In certain embodiments, the rigid columns can comprise a rigid or felted foam. In some embodiments, the columns may have a circular cross-section, and may have diameters for example from 5 mm to 10 mm (or about 5 mm to about 10 mm) with a spacing of 5 mm to 10 mm (or about 5 mm to about 10 mm) around them. For example, the diameter of the column can be about 1 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, or greater than 10 mm (or greater than about 10 mm). In certain embodiments, the spacing between the columns can range from about 1 mm to 5 mm, about 5 mm to 10 mm, about 10 mm to 15 mm, about 15 mm to 20 mm, or greater than 20 mm (or greater than about 20 mm).
In some embodiments (not shown but described as FIG. 14 in Provisional Application No. 61/651,483), a wound filler may comprise one or more conduits that extend to the wound-facing perimeter and are configured to communicate negative pressure. Here, once the wound is sealed under a drape, the one or more conduits can apply negative pressure to the wound, thereby contacting one or more areas on the inside perimeter of the wound. The wound filler can comprise fill material and extending members as described hereinbefore. The wound filler is preferably configured to contain one or more laces or filaments with free ends extending in a vertical direction away from the wound. Upon application of negative pressure, and once the edges of the wound have made contact with the wound filler, the one or more laces or filaments can be pulled so as to collapse the wound filler inward, thereby aiding in the closure of the wound. In some embodiments, the laces or filaments are attached to the extending members and may comprise any of the draw string embodiments previously described herein.
In some embodiments, any of the aforementioned wound fillers can comprise a dissolvable foam. In certain embodiments, the wound filler can comprise an area of dissolvable foam surrounding or surrounded by one or more regions of foam that do not dissolve under ordinary physiological conditions. In particular embodiments, the dissolvable foam region can be central and surrounded by one or more strips of non-dissolvable foam. In some embodiments, the dissolvable foam can also be in a ring configuration and surrounded at least on a horizontal plane by non-dissolvable foam (or vice-versa). In certain embodiments, when implanted into a wound, the dissolvable portions of foam can at least partly dissolve, for example upon contact with wound exudate, thereby providing additional space for the non-dissolvable foam to collapse toward. In preferable embodiments, this collapse can be used to promote horizontal closure of the wound. In some embodiments, the dissolvable foam can comprise polyvinyl alcohol foam (PVA).
In certain embodiments, the dissolvable foam can be replaced by a resorbable filler, for example a resorbable tissue filler scaffold. In some embodiments, this tissue filler can be constructed from biodegradable polymers such as polylactic acid, polyglycolic acid, or any combination of the two polymers. In particular embodiments, the resorbable scaffold can be configured to deliver beneficial molecules. In some embodiments, the scaffold is configured to deliver growth factors. In certain embodiments, the scaffold is configured to deliver antimicrobial molecules. In particular embodiments, such a scaffold can be seeded with beneficial cells, such as fibroblasts or stem cells. In some embodiments, such a scaffold can be seeded with keratinocytes.
In some embodiments, any of the aforementioned wound fillers can be constructed from a three-dimensional material comprising stiffer vertical components and compressible components extending in a lateral direction, such as 3D fabrics and fibers. In some embodiments, the material can present itself as a three-dimensional non-woven material. In particular embodiments, such a wound filler material can preferentially collapse or more readily collapse in a horizontal direction while resisting collapse in a vertical direction.
In some embodiments, any of the aforementioned wound filler materials can comprise a foam material with different-sized bubbles. In some embodiments, as smaller bubbles are more resistant to collapse than larger bubbles, the bubble sizes can be tailored to control the contraction of the wound filler. In certain embodiments, bubbles can be arranged in a gradient, such as a lengthwise or circular gradient, to control collapsibility of the wound filler. In certain embodiments, this arrangement of bubbles can be manufactured using a dual dispense injection process, wherein a first material having a first density (e.g., a first pore/bubble/void size) and a second material having a second density (e.g., a second pore/bubble/void size) are injected into a mold or a plurality of molds. In some embodiments, the second material can be the same material as the first material, but have a different pore size or different size voids or bubbles therein. In certain embodiments, foams of different pore, bubble, or void sizes or density can be coupled together.
Some embodiments can comprise foam with varying compressibility obtained by changing the chemistry or makeup of the material used to make the foam as foam is being produced. For example, without limitation, longer soft (more compressible) polymer blocks or plasticizers can be used to make all or a portion of the foam more compressible. In some embodiments, soft (more compressible) blocks or soft (more compressible) portions of the filler can be made from polypropylene glycol or polytetramethylene glycol, or other similar materials. In some embodiments, the filler can have soft (more compressible) blocks or soft (more compressible) portions made from any suitable sufficiently high molecular weight material.
In some embodiments, during manufacture of the foam material, the makeup of the material passing through the injectors or dispensers used to inject or dispense the foam material can be altered such that the density or stiffness of the foam changes along the length of the foam. For example, without limitation, the foam can be manufactured such that softer, more compressible portions are sandwiched or positioned between stiffer, less compressible portions of the same length of foam. Thereby, the foam having varying compressibility can be produced integrally. In certain embodiments, including any of the embodiments herein where the foam or filler can be produced in multiple stages, softer more compressible foam portions can be injected into, or otherwise inserted into voids or bubbles within a less compressible foam material or vice versa, or can be formed (i.e., injected) or positioned between portions of less compressible foam material. In some embodiments, the additional material if formed in separate foam blocks or layers, can be laminated or otherwise coupled with the other material or materials with which it is to be used.
In some embodiments, a method of treating a wound can include positioning any one of the aforementioned wound fillers into a wound bed and covering the wound filler with a wound cover. Applying negative pressure to such an embodiment can cause the wound filler to contract horizontally with the vertically extending members reducing vertical movement of the wound filler.
Other Negative Pressure Therapy Apparatuses, Dressings, Wound Fillers, and Methods
Further embodiments of negative pressure therapy apparatuses, dressings, wound fillers and methods of using the same that may be utilized alone or in combination with the embodiments described herein, and further description of the embodiments found above, are found in U.S. Provisional Application No. 61/651,483, filed May 24, 2012, the entirety of which is hereby incorporated by reference. Portions of U.S. Provisional Application No. 61/651,483, which was included as an Appendix in U.S. Provisional Application No. 61/782,270, are reproduced below.
In a manner similar to the embodiment disclosed in
In this embodiment, the treatment device comprises a wound filler (e.g., foam) with telescopic tubes. The wound filler can be placed into a wound cavity with telescopic tubes positioned across the major axis of the wound and on top of the filler and periwound area. In other embodiments, the tubes can be integrated through the wound filler. A drape can then be placed over the treatment device, and the entire assembly fluidically attached to a source of negative pressure.
Application of negative pressure will cause the filler to collapse in a horizontal plane, but the tubes will reduce vertical movement of the filler (which would otherwise apply a horizontal force that makes wound closure more difficult). As the wound margins contract, the telescopic tubes will collapse along their length, thus closing together with the wound.
With reference to
In some embodiments, the wound filler can comprise entirely or in part an elastomeric shape-memory foam. The shape-memory foam can be pre-stressed into an extended configuration, and, upon exposure to moisture, will contract. An example of a suitable shape-memory foam is Elast-Eon™.
In this embodiment, a wound filler has one or more draw strings or cords extending through it, preferably with free ends extending from the top side of the wound filler (i.e., the side of the filler that will face outward when the wound filler is inserted into a wound). When negative pressure is applied, the draw strings can be tightened, for example by pulling in a vertical direction, thereby causing the foam to contract substantially only in a horizontal plane.
With reference to
In a manner similar to the embodiment illustrated in
In
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.
Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.
This application is a continuation application of U.S. application Ser. No. 14/403,163, filed Nov. 21, 2014, which is a national stage application of International Patent Application No. PCT/IB2013/001555, filed on May 23, 2013, which claims the benefit of U.S. Provisional Application Nos. 61/651,483, filed May 24, 2012, entitled DEVICES AND METHODS FOR TREATING AND CLOSING WOUNDS WITH NEGATIVE PRESSURE, and 61/782,270, filed Mar. 14, 2013, entitled DEVICES AND METHODS FOR TREATING AND CLOSING WOUNDS WITH NEGATIVE PRESSURE, the contents of which are hereby incorporated by reference in their entireties as if fully set forth herein. The benefit of priority to the foregoing applications is claimed under the appropriate legal basis including, without limitation, under 35 U.S.C. § 119(e).
Number | Name | Date | Kind |
---|---|---|---|
1006716 | Bloomer | Oct 1911 | A |
3014483 | Frank et al. | Dec 1961 | A |
3194239 | Sullivan | Jul 1965 | A |
3578003 | Everett | May 1971 | A |
3789851 | Leveen | Feb 1974 | A |
3812616 | Koziol | May 1974 | A |
3952633 | Nakai | Apr 1976 | A |
4000845 | Zeller | Jan 1977 | A |
4467805 | Fukuda | Aug 1984 | A |
4608041 | Nielsen | Aug 1986 | A |
4637819 | Ouellette et al. | Jan 1987 | A |
4699134 | Samuelsen | Oct 1987 | A |
4771482 | Shlenker | Sep 1988 | A |
4815468 | Annand | Mar 1989 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5264218 | Rogozinski | Nov 1993 | A |
5332149 | Gepfer | Jul 1994 | A |
5368910 | Langdon | Nov 1994 | A |
5368930 | Samples | Nov 1994 | A |
5376067 | Daneshvar | Dec 1994 | A |
5409472 | Rawlings et al. | Apr 1995 | A |
5415715 | Delage et al. | May 1995 | A |
5423857 | Rosenman et al. | Jun 1995 | A |
5512041 | Bogart | Apr 1996 | A |
5514105 | Goodman, Jr. et al. | May 1996 | A |
5562107 | Lavender et al. | Oct 1996 | A |
5584859 | Brotz | Dec 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5695777 | Donovan et al. | Dec 1997 | A |
5853863 | Kim | Dec 1998 | A |
5928210 | Ouellette et al. | Jul 1999 | A |
5960497 | Castellino et al. | Oct 1999 | A |
6000403 | Cantwell | Dec 1999 | A |
6080168 | Levin et al. | Jun 2000 | A |
6086591 | Bojarski | Jul 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6176868 | Detour | Jan 2001 | B1 |
6291050 | Cree et al. | Sep 2001 | B1 |
6398767 | Fleischmann | Jun 2002 | B1 |
6471715 | Weiss | Oct 2002 | B1 |
6500112 | Khouri | Dec 2002 | B1 |
6503208 | Skovlund | Jan 2003 | B1 |
6530941 | Muller et al. | Mar 2003 | B1 |
6548727 | Swenson | Apr 2003 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6566575 | Stickels et al. | May 2003 | B1 |
6641575 | Lonky | Nov 2003 | B1 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6695823 | Lina et al. | Feb 2004 | B1 |
6712830 | Esplin | Mar 2004 | B2 |
6712839 | Lonne | Mar 2004 | B1 |
6767334 | Randolph | Jul 2004 | B1 |
6770794 | Fleischmann | Aug 2004 | B2 |
6776769 | Smith | Aug 2004 | B2 |
6787682 | Gilman | Sep 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6883531 | Perttu | Apr 2005 | B1 |
6893452 | Jacobs | May 2005 | B2 |
6936037 | Bubb et al. | Aug 2005 | B2 |
6951553 | Bubb et al. | Oct 2005 | B2 |
6977323 | Swenson | Dec 2005 | B1 |
6994702 | Johnson | Feb 2006 | B1 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7025755 | Epstein et al. | Apr 2006 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7117869 | Heaton et al. | Oct 2006 | B2 |
7128735 | Weston et al. | Oct 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7153312 | Torrie et al. | Dec 2006 | B1 |
7156862 | Jacobs et al. | Jan 2007 | B2 |
7172615 | Morriss et al. | Feb 2007 | B2 |
7189238 | Lombardo et al. | Mar 2007 | B2 |
7196054 | Drohan et al. | Mar 2007 | B1 |
7198046 | Argenta et al. | Apr 2007 | B1 |
7216651 | Argenta et al. | May 2007 | B2 |
D544092 | Lewis | Jun 2007 | S |
7262174 | Jiang et al. | Aug 2007 | B2 |
7279612 | Heaton et al. | Oct 2007 | B1 |
7315183 | Hinterscher | Jan 2008 | B2 |
7351250 | Zamierowski | Apr 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7367342 | Butler | May 2008 | B2 |
7381211 | Zamierowski | Jun 2008 | B2 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7413571 | Zamierowski | Aug 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7494482 | Orgill et al. | Feb 2009 | B2 |
7524315 | Blott et al. | Apr 2009 | B2 |
7534240 | Johnson | May 2009 | B1 |
7540848 | Hannigan et al. | Jun 2009 | B2 |
7553306 | Hunt et al. | Jun 2009 | B1 |
7553923 | Williams et al. | Jun 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7578532 | Schiebler | Aug 2009 | B2 |
D602583 | Pidgeon et al. | Oct 2009 | S |
7611500 | Lina et al. | Nov 2009 | B1 |
7612248 | Burton et al. | Nov 2009 | B2 |
7615036 | Joshi et al. | Nov 2009 | B2 |
7617762 | Ragner | Nov 2009 | B1 |
7618382 | Vogel et al. | Nov 2009 | B2 |
7622629 | Aali | Nov 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7645269 | Zamierowski | Jan 2010 | B2 |
7651484 | Heaton et al. | Jan 2010 | B2 |
7670323 | Hunt et al. | Mar 2010 | B2 |
7678102 | Heaton | Mar 2010 | B1 |
7683667 | Kim et al. | Mar 2010 | B2 |
7699823 | Haggstrom et al. | Apr 2010 | B2 |
7699830 | Martin et al. | Apr 2010 | B2 |
7699831 | Bengtson et al. | Apr 2010 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
7708724 | Weston et al. | May 2010 | B2 |
7713743 | Villanueva et al. | May 2010 | B2 |
7722528 | Arnal et al. | May 2010 | B2 |
7723560 | Lockwood et al. | May 2010 | B2 |
7753894 | Blott et al. | Jul 2010 | B2 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7776028 | Miller et al. | Aug 2010 | B2 |
7777522 | Yang et al. | Aug 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
D625801 | Pidgeon et al. | Oct 2010 | S |
7811269 | Boynton et al. | Oct 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7820453 | Heylen et al. | Oct 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7863495 | Aali | Jan 2011 | B2 |
7892181 | Christensen et al. | Feb 2011 | B2 |
7896856 | Petrosenko et al. | Mar 2011 | B2 |
7909805 | Weston et al. | Mar 2011 | B2 |
7910789 | Sinyagin | Mar 2011 | B2 |
7931774 | Hall et al. | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7976524 | Kudo et al. | Jul 2011 | B2 |
7981098 | Boehringer et al. | Jul 2011 | B2 |
8030534 | Radl et al. | Oct 2011 | B2 |
8057447 | Olson et al. | Nov 2011 | B2 |
8062272 | Weston et al. | Nov 2011 | B2 |
8062295 | McDevitt et al. | Nov 2011 | B2 |
8062331 | Zamierowski | Nov 2011 | B2 |
8067662 | Aali et al. | Nov 2011 | B2 |
8070773 | Zamierowski | Dec 2011 | B2 |
8080702 | Blott et al. | Dec 2011 | B2 |
8100887 | Weston et al. | Jan 2012 | B2 |
8114126 | Heaton et al. | Feb 2012 | B2 |
8123781 | Zamierowski | Feb 2012 | B2 |
8128615 | Blott et al. | Mar 2012 | B2 |
8129580 | Wilkes et al. | Mar 2012 | B2 |
8142419 | Heaton et al. | Mar 2012 | B2 |
8162909 | Blott et al. | Apr 2012 | B2 |
8172816 | Kazala, Jr. et al. | May 2012 | B2 |
8182413 | Browning | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8192409 | Hardman et al. | Jun 2012 | B2 |
8197467 | Heaton et al. | Jun 2012 | B2 |
8207392 | Haggstrom et al. | Jun 2012 | B2 |
8215929 | Shen et al. | Jul 2012 | B2 |
8235955 | Blott et al. | Aug 2012 | B2 |
8235972 | Adahan | Aug 2012 | B2 |
8246590 | Hu et al. | Aug 2012 | B2 |
8246606 | Stevenson et al. | Aug 2012 | B2 |
8246607 | Karpowicz et al. | Aug 2012 | B2 |
8257328 | Augustine et al. | Sep 2012 | B2 |
8273105 | Cohen et al. | Sep 2012 | B2 |
8298200 | Vess et al. | Oct 2012 | B2 |
8328776 | Kelch et al. | Dec 2012 | B2 |
8337411 | Nishtala et al. | Dec 2012 | B2 |
8353931 | Stopek et al. | Jan 2013 | B2 |
8357131 | Olson | Jan 2013 | B2 |
8362315 | Aali | Jan 2013 | B2 |
8376972 | Fleischmann | Feb 2013 | B2 |
8399730 | Kazala, Jr. et al. | Mar 2013 | B2 |
8430867 | Robinson et al. | Apr 2013 | B2 |
8439882 | Kelch | May 2013 | B2 |
8444392 | Turner et al. | May 2013 | B2 |
8444611 | Wilkes et al. | May 2013 | B2 |
8447375 | Shuler | May 2013 | B2 |
8454990 | Canada et al. | Jun 2013 | B2 |
8460255 | Joshi et al. | Jun 2013 | B2 |
8460257 | Locke et al. | Jun 2013 | B2 |
8481804 | Timothy | Jul 2013 | B2 |
8486032 | Seegert et al. | Jul 2013 | B2 |
8500704 | Boehringer et al. | Aug 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8523832 | Seegert | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8562576 | Hu et al. | Oct 2013 | B2 |
8608776 | Coward et al. | Dec 2013 | B2 |
8622981 | Hartwell et al. | Jan 2014 | B2 |
8628505 | Weston | Jan 2014 | B2 |
8632523 | Eriksson et al. | Jan 2014 | B2 |
8673992 | Eckstein et al. | Mar 2014 | B2 |
8679080 | Kazala, Jr. et al. | Mar 2014 | B2 |
8679153 | Dennis | Mar 2014 | B2 |
8680360 | Greener et al. | Mar 2014 | B2 |
8708984 | Robinson et al. | Apr 2014 | B2 |
8715256 | Greener | May 2014 | B2 |
8721629 | Hardman et al. | May 2014 | B2 |
8746662 | Poppe | Jun 2014 | B2 |
8747375 | Barta et al. | Jun 2014 | B2 |
8764732 | Hartwell | Jul 2014 | B2 |
8784392 | Vess et al. | Jul 2014 | B2 |
8791315 | Lattimore et al. | Jul 2014 | B2 |
8791316 | Greener | Jul 2014 | B2 |
8801685 | Armstrong et al. | Aug 2014 | B2 |
8802916 | Edward et al. | Aug 2014 | B2 |
8814842 | Coulthard et al. | Aug 2014 | B2 |
8821535 | Greener | Sep 2014 | B2 |
8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
8853486 | Wild et al. | Oct 2014 | B2 |
8882730 | Zimnitsky et al. | Nov 2014 | B2 |
8936618 | Sealy et al. | Jan 2015 | B2 |
8945030 | Weston et al. | Feb 2015 | B2 |
8951235 | Allen et al. | Feb 2015 | B2 |
8956336 | Haggstrom et al. | Feb 2015 | B2 |
9044579 | Blott et al. | Jun 2015 | B2 |
9050398 | Armstrong et al. | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9084845 | Adie et al. | Jul 2015 | B2 |
9180132 | Fein et al. | Nov 2015 | B2 |
9180231 | Greener | Nov 2015 | B2 |
9204801 | Locke et al. | Dec 2015 | B2 |
9220822 | Hartwell | Dec 2015 | B2 |
9226737 | Dunn | Jan 2016 | B2 |
9301742 | Dunn | Apr 2016 | B2 |
9339248 | Tout et al. | May 2016 | B2 |
9352076 | Boynton et al. | May 2016 | B2 |
9408755 | Larsson et al. | Aug 2016 | B2 |
9421132 | Dunn et al. | Aug 2016 | B2 |
9555170 | Fleischmann | Jan 2017 | B2 |
9597484 | Dunn | Mar 2017 | B2 |
9655807 | Locke et al. | May 2017 | B2 |
9737649 | Begin et al. | Aug 2017 | B2 |
9757500 | Locke et al. | Sep 2017 | B2 |
9770368 | Robinson et al. | Sep 2017 | B2 |
9801986 | Greener | Oct 2017 | B2 |
9820888 | Greener et al. | Nov 2017 | B2 |
D805039 | Dejanovic et al. | Dec 2017 | S |
9844472 | Hammond et al. | Dec 2017 | B2 |
9849023 | Hall et al. | Dec 2017 | B2 |
9895270 | Coward et al. | Feb 2018 | B2 |
9962295 | Dunn et al. | May 2018 | B2 |
10070994 | Dodd et al. | Sep 2018 | B2 |
10117782 | Dagger et al. | Nov 2018 | B2 |
10124098 | Dunn et al. | Nov 2018 | B2 |
10130520 | Dunn et al. | Nov 2018 | B2 |
10143485 | Locke et al. | Dec 2018 | B2 |
10179073 | Hartwell et al. | Jan 2019 | B2 |
10201642 | Hartwell et al. | Feb 2019 | B2 |
10245185 | Hicks et al. | Apr 2019 | B2 |
10405861 | Dunn | Sep 2019 | B2 |
10537657 | Phillips et al. | Jan 2020 | B2 |
10575991 | Dunn | Mar 2020 | B2 |
10660992 | Canner et al. | May 2020 | B2 |
10814049 | Dunn | Oct 2020 | B2 |
11083631 | Dunn et al. | Aug 2021 | B2 |
20010029956 | Argenta et al. | Oct 2001 | A1 |
20010034499 | Sessions et al. | Oct 2001 | A1 |
20020022861 | Jacobs et al. | Feb 2002 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20030108587 | Orgill et al. | Jun 2003 | A1 |
20030114816 | Underhill et al. | Jun 2003 | A1 |
20030114818 | Benecke et al. | Jun 2003 | A1 |
20030114821 | Underhill et al. | Jun 2003 | A1 |
20030120249 | Wulz et al. | Jun 2003 | A1 |
20030121588 | Pargass et al. | Jul 2003 | A1 |
20030178274 | Chi | Sep 2003 | A1 |
20030220660 | Kortenbach et al. | Nov 2003 | A1 |
20040006319 | Lina et al. | Jan 2004 | A1 |
20040010275 | Jacobs et al. | Jan 2004 | A1 |
20040030304 | Hunt et al. | Feb 2004 | A1 |
20040054346 | Zhu et al. | Mar 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040147465 | Jiang et al. | Jul 2004 | A1 |
20040162512 | Liedtke et al. | Aug 2004 | A1 |
20040243073 | Lockwood et al. | Dec 2004 | A1 |
20040267312 | Kanner et al. | Dec 2004 | A1 |
20050107731 | Sessions | May 2005 | A1 |
20050119694 | Jacobs et al. | Jun 2005 | A1 |
20050131414 | Chana | Jun 2005 | A1 |
20050142331 | Anderson et al. | Jun 2005 | A1 |
20050182445 | Zamierowski | Aug 2005 | A1 |
20050209574 | Boehringer et al. | Sep 2005 | A1 |
20050222544 | Weston | Oct 2005 | A1 |
20050222613 | Ryan | Oct 2005 | A1 |
20050240220 | Zamierowski | Oct 2005 | A1 |
20050258887 | Ito et al. | Nov 2005 | A1 |
20050267424 | Eriksson et al. | Dec 2005 | A1 |
20060020269 | Cheng | Jan 2006 | A1 |
20060058842 | Wilke et al. | Mar 2006 | A1 |
20060064124 | Zhu et al. | Mar 2006 | A1 |
20060069357 | Marasco | Mar 2006 | A1 |
20060079599 | Arthur et al. | Apr 2006 | A1 |
20060135921 | Wiercinski et al. | Jun 2006 | A1 |
20060213527 | Argenta et al. | Sep 2006 | A1 |
20060217795 | Besselink et al. | Sep 2006 | A1 |
20060257457 | Gorman et al. | Nov 2006 | A1 |
20060259074 | Kelleher et al. | Nov 2006 | A1 |
20060271018 | Korf | Nov 2006 | A1 |
20070027414 | Hoffman et al. | Feb 2007 | A1 |
20070027475 | Pagedas | Feb 2007 | A1 |
20070032755 | Walsh | Feb 2007 | A1 |
20070032763 | Vogel | Feb 2007 | A1 |
20070038172 | Zamierowski | Feb 2007 | A1 |
20070052144 | Knirck et al. | Mar 2007 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070104941 | Kameda et al. | May 2007 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20070123816 | Zhu et al. | May 2007 | A1 |
20070123973 | Roth et al. | May 2007 | A1 |
20070129660 | McLeod et al. | Jun 2007 | A1 |
20070149910 | Zocher | Jun 2007 | A1 |
20070161937 | Aali | Jul 2007 | A1 |
20070179421 | Farrow | Aug 2007 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070213597 | Wooster | Sep 2007 | A1 |
20070219513 | Lina et al. | Sep 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20070282309 | Bengtson et al. | Dec 2007 | A1 |
20070282374 | Sogard et al. | Dec 2007 | A1 |
20070299541 | Chernomorsky et al. | Dec 2007 | A1 |
20080041401 | Casola et al. | Feb 2008 | A1 |
20080103462 | Wenzel et al. | May 2008 | A1 |
20080108977 | Heaton et al. | May 2008 | A1 |
20080167593 | Fleischmann | Jul 2008 | A1 |
20080177253 | Boehringer et al. | Jul 2008 | A1 |
20080243096 | Svedman et al. | Oct 2008 | A1 |
20080275409 | Kane et al. | Nov 2008 | A1 |
20080287973 | Aster et al. | Nov 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20090005716 | Abuzaina et al. | Jan 2009 | A1 |
20090005744 | Karpowicz et al. | Jan 2009 | A1 |
20090018578 | Wilke et al. | Jan 2009 | A1 |
20090018579 | Wilke et al. | Jan 2009 | A1 |
20090043268 | Eddy et al. | Feb 2009 | A1 |
20090069760 | Finklestein | Mar 2009 | A1 |
20090069904 | Picha | Mar 2009 | A1 |
20090093550 | Rolfes et al. | Apr 2009 | A1 |
20090099519 | Kaplan | Apr 2009 | A1 |
20090105670 | Bentley et al. | Apr 2009 | A1 |
20090131888 | Joshi | May 2009 | A1 |
20090137973 | Karpowicz et al. | May 2009 | A1 |
20090204423 | Degheest et al. | Aug 2009 | A1 |
20090227938 | Fasching et al. | Sep 2009 | A1 |
20090227969 | Jaeb et al. | Sep 2009 | A1 |
20090246238 | Gorman et al. | Oct 2009 | A1 |
20090259203 | Hu et al. | Oct 2009 | A1 |
20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299256 | Barta et al. | Dec 2009 | A1 |
20090299303 | Seegert | Dec 2009 | A1 |
20090299307 | Barta et al. | Dec 2009 | A1 |
20090299341 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299342 | Cavanaugh, II et al. | Dec 2009 | A1 |
20090312685 | Olsen et al. | Dec 2009 | A1 |
20100022972 | Lina et al. | Jan 2010 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100028407 | Del et al. | Feb 2010 | A1 |
20100030132 | Niezgoda et al. | Feb 2010 | A1 |
20100036333 | Schenk, III | Feb 2010 | A1 |
20100047324 | Fritz et al. | Feb 2010 | A1 |
20100081983 | Zocher et al. | Apr 2010 | A1 |
20100087854 | Stopek et al. | Apr 2010 | A1 |
20100100022 | Greener et al. | Apr 2010 | A1 |
20100100063 | Joshi et al. | Apr 2010 | A1 |
20100106106 | Heaton et al. | Apr 2010 | A1 |
20100106184 | Coward et al. | Apr 2010 | A1 |
20100106188 | Heaton et al. | Apr 2010 | A1 |
20100121286 | Locke et al. | May 2010 | A1 |
20100121287 | Smith et al. | May 2010 | A1 |
20100125233 | Edward | May 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100137890 | Martinez et al. | Jun 2010 | A1 |
20100150991 | Bernstein | Jun 2010 | A1 |
20100160874 | Robinson et al. | Jun 2010 | A1 |
20100160876 | Robinson et al. | Jun 2010 | A1 |
20100160901 | Hu et al. | Jun 2010 | A1 |
20100179515 | Swain et al. | Jul 2010 | A1 |
20100198128 | Turnlund et al. | Aug 2010 | A1 |
20100211030 | Turner et al. | Aug 2010 | A1 |
20100256672 | Weinberg et al. | Oct 2010 | A1 |
20100262092 | Hartwell | Oct 2010 | A1 |
20100262106 | Hartwell | Oct 2010 | A1 |
20100262126 | Hu et al. | Oct 2010 | A1 |
20100280468 | Haggstrom et al. | Nov 2010 | A1 |
20100292717 | Petter-Puchner et al. | Nov 2010 | A1 |
20100298866 | Fischvogt | Nov 2010 | A1 |
20100305490 | Coulthard et al. | Dec 2010 | A1 |
20100312159 | Aali et al. | Dec 2010 | A1 |
20100318046 | Boehringer et al. | Dec 2010 | A1 |
20110004173 | Hu et al. | Jan 2011 | A1 |
20110009838 | Greener | Jan 2011 | A1 |
20110015594 | Hu et al. | Jan 2011 | A1 |
20110015595 | Robinson et al. | Jan 2011 | A1 |
20110021965 | Karp et al. | Jan 2011 | A1 |
20110022082 | Burke et al. | Jan 2011 | A1 |
20110054283 | Shuler | Mar 2011 | A1 |
20110054365 | Greener | Mar 2011 | A1 |
20110059291 | Boyce et al. | Mar 2011 | A1 |
20110060204 | Weston | Mar 2011 | A1 |
20110066096 | Svedman | Mar 2011 | A1 |
20110077605 | Karpowicz et al. | Mar 2011 | A1 |
20110082480 | Viola | Apr 2011 | A1 |
20110105963 | Hu et al. | May 2011 | A1 |
20110106026 | Wu et al. | May 2011 | A1 |
20110110996 | Schoenberger et al. | May 2011 | A1 |
20110112458 | Holm et al. | May 2011 | A1 |
20110113559 | Dodd | May 2011 | A1 |
20110130774 | Criscuolo et al. | Jun 2011 | A1 |
20110152800 | Eckstein et al. | Jun 2011 | A1 |
20110172760 | Anderson | Jul 2011 | A1 |
20110178451 | Robinson | Jul 2011 | A1 |
20110196420 | Ebner | Aug 2011 | A1 |
20110213287 | Lattimore et al. | Sep 2011 | A1 |
20110213319 | Blott et al. | Sep 2011 | A1 |
20110224631 | Simmons et al. | Sep 2011 | A1 |
20110224632 | Zimnitsky et al. | Sep 2011 | A1 |
20110224634 | Locke et al. | Sep 2011 | A1 |
20110236460 | Stopek et al. | Sep 2011 | A1 |
20110238026 | Zhang et al. | Sep 2011 | A1 |
20110238095 | Browning | Sep 2011 | A1 |
20110238110 | Wilke et al. | Sep 2011 | A1 |
20110245682 | Robinson et al. | Oct 2011 | A1 |
20110245788 | Marquez Canada | Oct 2011 | A1 |
20110264138 | Avelar et al. | Oct 2011 | A1 |
20110270201 | Bubb et al. | Nov 2011 | A1 |
20110270301 | Cornet et al. | Nov 2011 | A1 |
20110275964 | Greener | Nov 2011 | A1 |
20110282136 | Browning | Nov 2011 | A1 |
20110282309 | Adie et al. | Nov 2011 | A1 |
20110282310 | Boehringer et al. | Nov 2011 | A1 |
20110305736 | Wieland et al. | Dec 2011 | A1 |
20110313374 | Lockwood et al. | Dec 2011 | A1 |
20110319804 | Greener | Dec 2011 | A1 |
20120004631 | Hartwell | Jan 2012 | A9 |
20120010637 | Stopek et al. | Jan 2012 | A1 |
20120016321 | Wu et al. | Jan 2012 | A1 |
20120016322 | Coulthard et al. | Jan 2012 | A1 |
20120029449 | Khosrowshahi | Feb 2012 | A1 |
20120029455 | Perez-Foullerat et al. | Feb 2012 | A1 |
20120035560 | Eddy et al. | Feb 2012 | A1 |
20120041402 | Greener | Feb 2012 | A1 |
20120059399 | Hoke et al. | Mar 2012 | A1 |
20120059412 | Fleischmann | Mar 2012 | A1 |
20120065664 | Avitable et al. | Mar 2012 | A1 |
20120071841 | Bengtson | Mar 2012 | A1 |
20120073736 | O'Connor et al. | Mar 2012 | A1 |
20120083755 | Lina et al. | Apr 2012 | A1 |
20120095426 | Visscher et al. | Apr 2012 | A1 |
20120109188 | Viola | May 2012 | A1 |
20120121556 | Fraser et al. | May 2012 | A1 |
20120123358 | Hall et al. | May 2012 | A1 |
20120130327 | Marquez | May 2012 | A1 |
20120136326 | Croizat et al. | May 2012 | A1 |
20120136328 | Johannison et al. | May 2012 | A1 |
20120143113 | Robinson et al. | Jun 2012 | A1 |
20120143158 | Yang et al. | Jun 2012 | A1 |
20120144989 | Du et al. | Jun 2012 | A1 |
20120150078 | Chen et al. | Jun 2012 | A1 |
20120150133 | Heaton et al. | Jun 2012 | A1 |
20120157942 | Weston | Jun 2012 | A1 |
20120165764 | Allen et al. | Jun 2012 | A1 |
20120172778 | Rastegar et al. | Jul 2012 | A1 |
20120172926 | Hotter | Jul 2012 | A1 |
20120191054 | Kazala, Jr. et al. | Jul 2012 | A1 |
20120191132 | Sargeant | Jul 2012 | A1 |
20120197415 | Montanari et al. | Aug 2012 | A1 |
20120203189 | Barta et al. | Aug 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20120209227 | Dunn | Aug 2012 | A1 |
20120220968 | Confalone et al. | Aug 2012 | A1 |
20120222687 | Czajka, Jr. et al. | Sep 2012 | A1 |
20120238931 | Rastegar et al. | Sep 2012 | A1 |
20120253302 | Corley | Oct 2012 | A1 |
20120277773 | Sargeant et al. | Nov 2012 | A1 |
20120302440 | Theliander et al. | Nov 2012 | A1 |
20130012891 | Gross et al. | Jan 2013 | A1 |
20130023842 | Song | Jan 2013 | A1 |
20130066365 | Belson et al. | Mar 2013 | A1 |
20130096518 | Hall et al. | Apr 2013 | A1 |
20130110058 | Adie et al. | May 2013 | A1 |
20130110066 | Sharma | May 2013 | A1 |
20130131564 | Locke et al. | May 2013 | A1 |
20130138054 | Fleischmann | May 2013 | A1 |
20130150813 | Gordon et al. | Jun 2013 | A1 |
20130150814 | Buan | Jun 2013 | A1 |
20130190705 | Vess et al. | Jul 2013 | A1 |
20130197457 | Kazala, Jr. et al. | Aug 2013 | A1 |
20130204213 | Heagle et al. | Aug 2013 | A1 |
20130245527 | Croizat et al. | Sep 2013 | A1 |
20130253401 | Locke et al. | Sep 2013 | A1 |
20130274717 | Dunn | Oct 2013 | A1 |
20130310781 | Phillips et al. | Nov 2013 | A1 |
20130317465 | Seegert | Nov 2013 | A1 |
20130325142 | Hunter et al. | Dec 2013 | A1 |
20130331757 | Belson | Dec 2013 | A1 |
20140066868 | Freedman et al. | Mar 2014 | A1 |
20140068914 | Coward et al. | Mar 2014 | A1 |
20140088455 | Christensen et al. | Mar 2014 | A1 |
20140094730 | Greener et al. | Apr 2014 | A1 |
20140109560 | Ilievski et al. | Apr 2014 | A1 |
20140163415 | Zaiken et al. | Jun 2014 | A1 |
20140180225 | Dunn | Jun 2014 | A1 |
20140180229 | Fuller et al. | Jun 2014 | A1 |
20140194836 | Kazala, Jr. et al. | Jul 2014 | A1 |
20140194837 | Robinson et al. | Jul 2014 | A1 |
20140195004 | Engqvist et al. | Jul 2014 | A9 |
20140213994 | Hardman et al. | Jul 2014 | A1 |
20140228789 | Wilkes et al. | Aug 2014 | A1 |
20140249495 | Mumby et al. | Sep 2014 | A1 |
20140316359 | Collinson et al. | Oct 2014 | A1 |
20140336602 | Karpowicz et al. | Nov 2014 | A1 |
20140343517 | Jameson | Nov 2014 | A1 |
20140343518 | Riesinger | Nov 2014 | A1 |
20150000018 | Brandt | Jan 2015 | A1 |
20150005722 | Hu et al. | Jan 2015 | A1 |
20150025484 | Simmons et al. | Jan 2015 | A1 |
20150030806 | Fink | Jan 2015 | A1 |
20150057762 | Harms et al. | Feb 2015 | A1 |
20150065805 | Edmondson et al. | Mar 2015 | A1 |
20150065968 | Sealy et al. | Mar 2015 | A1 |
20150075697 | Gildersleeve | Mar 2015 | A1 |
20150080947 | Greener | Mar 2015 | A1 |
20150100008 | Chatterjee | Apr 2015 | A1 |
20150112290 | Dunn | Apr 2015 | A1 |
20150112311 | Hammond et al. | Apr 2015 | A1 |
20150119837 | Thompson, Jr. et al. | Apr 2015 | A1 |
20150119865 | Barta et al. | Apr 2015 | A1 |
20150148760 | Dodd et al. | May 2015 | A1 |
20150150729 | Dagger et al. | Jun 2015 | A1 |
20150157758 | Blücher et al. | Jun 2015 | A1 |
20150159066 | Hartwell et al. | Jun 2015 | A1 |
20150164174 | West | Jun 2015 | A1 |
20150174304 | Askem et al. | Jun 2015 | A1 |
20150190288 | Dunn et al. | Jul 2015 | A1 |
20150196431 | Dunn et al. | Jul 2015 | A1 |
20150216732 | Hartwell et al. | Aug 2015 | A1 |
20150320434 | Ingram et al. | Nov 2015 | A1 |
20150320602 | Locke et al. | Nov 2015 | A1 |
20150374561 | Hubbard, Jr. et al. | Dec 2015 | A1 |
20160022885 | Dunn et al. | Jan 2016 | A1 |
20160030646 | Hartwell et al. | Feb 2016 | A1 |
20160067939 | Liebe et al. | Mar 2016 | A1 |
20160144085 | Melin et al. | May 2016 | A1 |
20160166744 | Hartwell | Jun 2016 | A1 |
20160184496 | Jaecklein et al. | Jun 2016 | A1 |
20160235897 | Boynton et al. | Aug 2016 | A1 |
20160354086 | Dunn | Dec 2016 | A1 |
20170007462 | Hartwell et al. | Jan 2017 | A1 |
20170007751 | Hartwell et al. | Jan 2017 | A1 |
20170065751 | Toth et al. | Mar 2017 | A1 |
20170156611 | Burnett et al. | Jun 2017 | A1 |
20170165116 | Dunn | Jun 2017 | A1 |
20170281838 | Dunn | Oct 2017 | A1 |
20180140465 | Dunn et al. | May 2018 | A1 |
20190105202 | Dunn et al. | Apr 2019 | A1 |
20190231944 | Dunn et al. | Aug 2019 | A1 |
20190262182 | Collinson et al. | Aug 2019 | A1 |
20200038023 | Dunn | Feb 2020 | A1 |
20200188564 | Dunn | Jun 2020 | A1 |
20200268562 | Dunn | Aug 2020 | A1 |
20200330661 | Canner et al. | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
2012261793 | Nov 2014 | AU |
2013206230 | May 2016 | AU |
2747743 | Jul 2010 | CA |
2701233 | Nov 2010 | CA |
1438904 | Aug 2003 | CN |
101112326 | Jan 2008 | CN |
101123930 | Feb 2008 | CN |
101208115 | Jun 2008 | CN |
101257938 | Sep 2008 | CN |
101588836 | Nov 2009 | CN |
101744688 | Jun 2010 | CN |
201519362 | Jul 2010 | CN |
102038575 | May 2011 | CN |
102046117 | May 2011 | CN |
102196830 | Sep 2011 | CN |
102256637 | Nov 2011 | CN |
102781380 | Nov 2012 | CN |
202568632 | Dec 2012 | CN |
103071197 | May 2013 | CN |
103405846 | Nov 2013 | CN |
103501709 | Jan 2014 | CN |
203408163 | Jan 2014 | CN |
104736110 | Jun 2015 | CN |
104768474 | Jul 2015 | CN |
104812343 | Jul 2015 | CN |
2949920 | Mar 1981 | DE |
102005007016 | Aug 2006 | DE |
102012001752 | Aug 2013 | DE |
1320342 | Jun 2003 | EP |
2094211 | Sep 2009 | EP |
2279016 | Feb 2011 | EP |
2341955 | Jul 2011 | EP |
2366721 | Sep 2011 | EP |
2367517 | Sep 2011 | EP |
2368523 | Sep 2011 | EP |
2404571 | Jan 2012 | EP |
2404626 | Jan 2012 | EP |
2529767 | Dec 2012 | EP |
2547375 | Jan 2013 | EP |
2563421 | Mar 2013 | EP |
2567682 | Mar 2013 | EP |
2567717 | Mar 2013 | EP |
2594299 | May 2013 | EP |
2601984 | Jun 2013 | EP |
2623137 | Aug 2013 | EP |
2759265 | Jul 2014 | EP |
2829287 | Jan 2015 | EP |
2872085 | May 2015 | EP |
3225261 | Oct 2017 | EP |
2389794 | Dec 2003 | GB |
2378392 | Jun 2004 | GB |
2423019 | Aug 2006 | GB |
2489947 | Oct 2012 | GB |
2496310 | May 2013 | GB |
2496310 | May 2013 | GB |
20140129 | Mar 2016 | IE |
S6257560 | Mar 1987 | JP |
H0341952 | Feb 1991 | JP |
H09-503923 | Apr 1997 | JP |
2006528038 | Dec 2006 | JP |
2007-505678 | Mar 2007 | JP |
2007-531567 | Nov 2007 | JP |
2008-529618 | Aug 2008 | JP |
2009525087 | Jul 2009 | JP |
2009-536851 | Oct 2009 | JP |
2010-526597 | Aug 2010 | JP |
2011-500170 | Jan 2011 | JP |
2011521 740 | Jul 2011 | JP |
2011-523575 | Aug 2011 | JP |
2011-526798 | Oct 2011 | JP |
2012-504460 | Feb 2012 | JP |
2012-105840 | Jun 2012 | JP |
2012-513826 | Jun 2012 | JP |
2012529974 | Nov 2012 | JP |
2013-526938 | Jun 2013 | JP |
2014168573 | Sep 2014 | JP |
1818103 | May 1993 | RU |
62504 | Apr 2007 | RU |
WO-199420041 | Sep 1994 | WO |
WO-200059424 | Oct 2000 | WO |
WO-200134223 | May 2001 | WO |
WO-2001085248 | Nov 2001 | WO |
WO-200189392 | Nov 2001 | WO |
WO-0205737 | Jan 2002 | WO |
WO-03003948 | Jan 2003 | WO |
WO-03049598 | Jun 2003 | WO |
WO-2004018020 | Mar 2004 | WO |
WO-2004037334 | May 2004 | WO |
WO-2005046761 | May 2005 | WO |
WO-2005105174 | Nov 2005 | WO |
WO 2006041496 | Apr 2006 | WO |
WO-2006046060 | May 2006 | WO |
WO-2006087021 | Aug 2006 | WO |
WO-2006100053 | Sep 2006 | WO |
WO-2007030601 | Mar 2007 | WO |
WO-2007120138 | Oct 2007 | WO |
WO-2007133618 | Nov 2007 | WO |
WO-2008005532 | Jan 2008 | WO |
WO 2008027449 | Mar 2008 | WO |
WO-2008039223 | Apr 2008 | WO |
WO-2008039839 | Apr 2008 | WO |
WO-2008064502 | Jun 2008 | WO |
WO-2008091521 | Jul 2008 | WO |
WO-2008104609 | Sep 2008 | WO |
WO-2009019495 | Feb 2009 | WO |
WO-2009071926 | Jun 2009 | WO |
WO-2009071933 | Jun 2009 | WO |
WO-2009093116 | Jul 2009 | WO |
WO-2009112848 | Sep 2009 | WO |
WO-2009114624 | Sep 2009 | WO |
WO-2009112062 | Sep 2009 | WO |
WO-2009158125 | Dec 2009 | WO |
WO-2009158132 | Dec 2009 | WO |
WO-2009156709 | Dec 2009 | WO |
WO-2010033725 | Mar 2010 | WO |
WO-2010051073 | May 2010 | WO |
WO-2010059612 | May 2010 | WO |
WO-2010075178 | Jul 2010 | WO |
WO-2010075180 | Jul 2010 | WO |
WO-2010078349 | Jul 2010 | WO |
WO-2010079359 | Jul 2010 | WO |
WO-2010092334 | Aug 2010 | WO |
WO-2010147535 | Dec 2010 | WO |
WO-2011023384 | Mar 2011 | WO |
WO-2011091169 | Jul 2011 | WO |
WO-2011106722 | Sep 2011 | WO |
WO-2011115908 | Sep 2011 | WO |
WO-2011116691 | Sep 2011 | WO |
WO-2011135284 | Nov 2011 | WO |
WO-2011135286 | Nov 2011 | WO |
WO-2011135287 | Nov 2011 | WO |
WO-2011144888 | Nov 2011 | WO |
WO-2011137230 | Nov 2011 | WO |
WO-2012021553 | Feb 2012 | WO |
WO-2012038727 | Mar 2012 | WO |
WO-2012069793 | May 2012 | WO |
WO 2012082716 | Jun 2012 | WO |
WO-2012087376 | Jun 2012 | WO |
WO-2012082876 | Jun 2012 | WO |
WO-2012106590 | Aug 2012 | WO |
WO-2012112204 | Aug 2012 | WO |
WO-2012136707 | Oct 2012 | WO |
WO-2012142473 | Oct 2012 | WO |
WO-2012156655 | Nov 2012 | WO |
WO-2013007973 | Jan 2013 | WO |
WO-2013012381 | Jan 2013 | WO |
WO-2013043258 | Mar 2013 | WO |
WO-2013074829 | May 2013 | WO |
WO-2013076450 | May 2013 | WO |
WO-2013071243 | May 2013 | WO |
WO-2013079447 | Jun 2013 | WO |
WO-2013079947 | Jun 2013 | WO |
WO-2013136181 | Sep 2013 | WO |
WO-2013175309 | Nov 2013 | WO |
WO-2013175310 | Nov 2013 | WO |
WO-2014013348 | Jan 2014 | WO |
WO-2014014842 | Jan 2014 | WO |
WO-2014014871 | Jan 2014 | WO |
WO-2014014922 | Jan 2014 | WO |
WO-2014024048 | Feb 2014 | WO |
WO-2014140578 | Sep 2014 | WO |
WO-2014165275 | Oct 2014 | WO |
WO-2014158526 | Oct 2014 | WO |
WO-2014178945 | Nov 2014 | WO |
WO-2014194786 | Dec 2014 | WO |
WO-2015008054 | Jan 2015 | WO |
WO-2015061352 | Apr 2015 | WO |
WO-2015109359 | Jul 2015 | WO |
WO-2015110409 | Jul 2015 | WO |
WO-2015110410 | Jul 2015 | WO |
WO-2015169637 | Nov 2015 | WO |
WO-2015172108 | Nov 2015 | WO |
WO-2015193257 | Dec 2015 | WO |
WO-2016018448 | Feb 2016 | WO |
WO-2016176513 | Nov 2016 | WO |
WO-2016179245 | Nov 2016 | WO |
WO-2016184913 | Nov 2016 | WO |
WO-2017063036 | Apr 2017 | WO |
WO-2017106576 | Jun 2017 | WO |
WO-2018038665 | Mar 2018 | WO |
WO-2018041805 | Mar 2018 | WO |
WO-2018044944 | Mar 2018 | WO |
WO-2018044949 | Mar 2018 | WO |
WO-2018237206 | Dec 2018 | WO |
Entry |
---|
“Definition of Oculiform,” Webster's Revised Unabridged Dictionary, accessed from The Free Dictionary on May 30, 2018 from URL: https://www.thefreedictionary.com/Oculiform, 1913, 1 page. |
International Preliminary Reporton Patentability for Application No. PCT/IB2013/001555, dated Nov. 25, 2014, 5 pages. |
International Search Report and Written Opinion for Application No. PCT/IB2013/001555, dated Sep. 3, 2013, 7 pages. |
Kapischke M., et al., “Self-Fixating Mesh for the Lichtenstein Procedure—a Prestudy,” Langenbecks Arch Surg, 2010, vol. 395, pp. 317-322. |
“Definition of 3D Printer,” American Heritage Dictionary of the English Language, Fifth Edition, accessed on Feb. 22, 2018 from URL: https://www.thefreedictionary.com, 2016, 1 page. |
“Definition of Adhere,” The Free Dictionary, accessed on Mar. 23, 2017 from http://www.thefreedictionary.com/adhere, 6 pages. |
“Definition of Throughout,” Merriam-Webster Dictionary, accessed on Aug. 29, 2017 from https://www.merriam-webster.com/dictionary/throughout, 11 pages. |
Bengezi et al., Elevation as a treatment for fasciotomy wound closure. Can J Plast Surg. 2013 Fall;21(3):192-4. |
Epstein et al., Lipoabdominoplasty Without Drains or Progressive Tension Sutures: An Analysis of 100 Consecutive Patients. Aesthetic Surgery Journal. Apr. 2015;35(4):434-440. |
Hougaard et al., The open abdomen: temporary closure with a modified negative pressure therapy technique. Int Wound J. Jun. 2014;11 Suppl 1:13-6. |
Jauregui et al., Fasciotomy closure techniques. J Orthop Surg (Hong Kong). Jan. 2017;25(1):2309499016684724. 8 pages. |
Macias et al., Decrease in Seroma Rate After Adopting Progressive Tension Sutures Without Drains: A Single Surgery Center Experience of 451 Abdominoplasties over 7 Years. Aesthetic Surgery Journal. Mar. 2016;36(9):1029-1035. |
Pollock et al., Progressive Tension Sutures in Abdominoplasty: A Review of 597 Consecutive Cases. Aesthetic Surgery Journal. Aug. 2012;32(6):729-742. |
Quaba et al., The no-drain, no-quilt abdominoplasty: a single-surgeon series of 271 patients. Plast Reconstr Surg. Mar. 2015;135(3):751-60. |
Rothenberg et al., Emerging Insights On Closed Incision NPWT And Transmetatarsal Amputations. http://www.podiatrytoday.com/emerging-insights-closed-incision-npwt-and-transmetatarsal-amputations. Apr. 2015;28(4):1-5. |
Number | Date | Country | |
---|---|---|---|
20190231599 A1 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
61782270 | Mar 2013 | US | |
61651483 | May 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14403163 | US | |
Child | 16177146 | US |